Literature DB >> 223499

In vitro system for studying the efficacy of antiviral agents in preventing the reactivation of latent herpes simplex virus.

C Wohlenberg, H Openshaw, A L Notkins.   

Abstract

Antiviral antibody and interferon did not prevent in vitro reactivation of herpes simplex virus in latently infected sensory ganglia. Phosphonoacetic acid and 9-beta-d-arabinofuranosyladenine blocked reactivation, but this treatment did not eradicate the latent infection.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 223499      PMCID： PMC352721          DOI： 10.1128/AAC.15.4.625

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Herpes simplex virus DNA and mRNA sequences in acutely and chronically infected trigeminal ganglia of mice.

Authors:  A Puga; J D Rosenthal; H Openshaw; A L Notkins
Journal:  Virology       Date:  1978-08       Impact factor: 3.616

Review 2.  Antiviral activity of interferons.

Authors:  R M Friedman
Journal:  Bacteriol Rev       Date:  1977-09

3.  Activation of latent herpes simplex by trigeminal sensory-root section.

Authors:  C A CARTON; E D KILBOURNE
Journal:  N Engl J Med       Date:  1952-01-31       Impact factor: 91.245

4.  Latent herpes simplex virus infection of mice. Infectious virus in homogenates of latently infected dorsal root ganglia.

Authors:  J Schwartz; W Whetsell; T S Elizan
Journal:  J Neuropathol Exp Neurol       Date:  1978-01       Impact factor: 3.685

Review 5.  Latent characteristics of selected herpesviruses.

Authors:  J G Stevens
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

Review 6.  Pharmacology and chemistry of some inhibitors of herpes replication.

Authors:  B W Fox
Journal:  J Antimicrob Chemother       Date:  1977-03       Impact factor: 5.790

7.  Persistent herpes simplex virus infection in rabbit trigeminal ganglia.

Authors:  J R Baringer; P Swoveland
Journal:  Lab Invest       Date:  1974-02       Impact factor: 5.662

8.  Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy.

Authors:  M A Walz; R W Price; A L Notkins
Journal:  Science       Date:  1974-06-14       Impact factor: 47.728

9.  Immune mechanisms by which the spread of viral infections is stopped.

Authors:  A L Notkins
Journal:  Cell Immunol       Date:  1974-03-30       Impact factor: 4.868

10.  Rational design of arabinosyl nucleosides as antitumor and antiviral agents.

Authors:  W E Müller
Journal:  Jpn J Antibiot       Date:  1977-12
View more
  6 in total

1.  Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.

Authors:  W G Liu; Z J Chen; J Z Song; Z X Ma
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.

Authors:  R J Klein; E DeStefano; A E Friedman-Kien; E Brady
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

3.  Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity.

Authors:  R H Bonneau; S R Jennings
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

4.  Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on the acute local phase of herpes simplex virus-induced skin infections in mice and the establishment of latency.

Authors:  R J Klein; A E Friedman-Kien
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Colonization of murine ganglia by a superinfecting strain of herpes simplex virus.

Authors:  B Meignier; B Norrild; B Roizman
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

6.  Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs.

Authors:  M Scriba
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.